These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1960360)

  • 41. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fecal occult blood testing for colorectal cancer screening: use the finger.
    Burke CA; Tadikonda L; Machicao V
    Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer.
    Rennert G; Kislitsin D; Brenner DE; Rennert HS; Lev Z
    Cancer Lett; 2007 Aug; 253(2):258-64. PubMed ID: 17349741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improving the effectiveness of fecal occult blood testing in a primary care clinic by direct colonoscopy referral for positive tests.
    Van Kleek E; Liu S; Conn LM; Hoadley A; Ho SB
    J Healthc Qual; 2010; 32(6):62-9. PubMed ID: 20946427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
    Lohsiriwat V
    Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologic significance of immunohistochemical fecal occult blood test in subjects receiving bidirectional endoscopy.
    Liu HH; Huang TW; Chen HL; Wang TH; Lin JT
    Hepatogastroenterology; 2003; 50(53):1390-2. PubMed ID: 14571744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Yield of dual endoscopy for positive fecal occult blood test.
    Ali M; Yaqub M; Haider Z; Anees I; Bhargava S; Gian J
    Am J Gastroenterol; 2003 Jan; 98(1):82-5. PubMed ID: 12526941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
    Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical diagnostic accuracy of faecal occult blood test for anal diseases.
    Nakama H; Kamijo N; Fujimori K; Horiuchi A; Fattah AS; Zhang B
    Int J Qual Health Care; 1997 Apr; 9(2):139-41. PubMed ID: 9154500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating follow-up of positive fecal occult blood test results: lessons learned.
    Chen ZJ; Kammer D; Bond JH; Ho SB
    J Healthc Qual; 2007; 29(5):16-20, 34. PubMed ID: 17892078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic accuracy of a single qualitative immunochemical fecal occult blood test coupled with physical measurements.
    Wu T; Kuo K; Wu Y; Lin K
    Chin Med J (Engl); 2014; 127(24):4164-70. PubMed ID: 25533816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
    McDonald R; Tomlins A; Smith S; Harmston C
    J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A population-based audit of the clinical use of faecal occult blood testing in primary care for colorectal cancer.
    Gillberg A; Ericsson E; Granstrom F; Olsson LI
    Colorectal Dis; 2012 Sep; 14(9):e539-46. PubMed ID: 22738077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience.
    Zappa M; Castiglione G; Paci E; Grazzini G; Rubeca T; Turco P; Crocetti E; Ciatto S
    Int J Cancer; 2001 Apr; 92(1):151-4. PubMed ID: 11279619
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.